ClinicalTrials.gg
Drug

Notiretatug rezetecan clinical trials

studies test it
19
open now
19
in phase 3
4
first study started
2022

How each study uses notiretatug rezetecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the notiretatug rezetecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

SHR-A2102
10
SHR-A2102 for Injection
3

In one entry with another drug

Given together, or one or the other

SHR-A2102 ; Adebrelimab injection
2

Studies by the year they started

19 studies that test it; most in 2025 (9)

Studies that test notiretatug rezetecan, by start year
YearStudies
20221
20232
20245
20259
20262

By phase

A phase 1/2 study counts in both.

Phase 1
6
Phase 2
14
Phase 3
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 13 · Other 6

Shanghai Hengrui Pharmaceutical Co., Ltd. (7) · Fudan University (4) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. (4) · Henan Cancer Hospital (2) · Shandong Suncadia Medicine Co., Ltd. (1) · Jiangsu HengRui Medicine Co., Ltd. (1)

Often tested with

Tested in the same studies.

Adebrelimab (7) · KRAS G12D Inhibitor HRS-4642 (2) · Trastuzumab rezetecan (2) · Tizetatug rezetecan (2) · Ruzaltatug rezetecan (2) · Famitinib (2) · Disitamab vedotin (2) · SHR-9839 (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 5

Studies that test notiretatug rezetecan.

Studies

Open first, then newest update. How each study uses notiretatug rezetecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 19

Given beside what is tested · 6 — notiretatug rezetecan is usual care or a partner of the new treatment

Codes

What other systems call notiretatug rezetecan · ClinicalTrials.gg INT016737

  • UNII (FDA) H423BH2FBANOTIRETATUG REZETECANOne source FDA
  • NCI Thesaurus C200198Notiretatug RezetecanOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.